GlobeNewswire by notified

Bavarian Nordic Enters a New Multi-Year Vaccine Contract with the Government of Canada

Share
  • New multi-year contract from Public Health Agency of Canada to procure IMVAMUNE® smallpox vaccine

COPENHAGEN, Denmark, June 7, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Public Health Agency of Canada (PHAC) will be purchasing IMVAMUNE® smallpox vaccine at a value of approximately USD 56 million. The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA.

Deliveries of vaccines under this five-year contract are expected to occur from 2023. Hence this contract will have no impact on the Company’s financial guidance for 2022.

In parallel, Bavarian Nordic continues to secure contracts with other countries, including Denmark, but also countries outside Europe, to supply the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: “We are pleased to extend our collaboration with the Government of Canada. We applaud the Government of Canada for their long-term planning, allowing us to execute on this contract in a timely manner.”

About the smallpox/monkeypox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada and the U.S. where the approval has been extended to include the monkeypox indication as the only vaccine having obtained this to-date.

Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, the vaccine has been supplied in response to non-endemic cases of monkeypox around the world.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 22 / 2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc’s share buybacks 28/06/202229.6.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 29/06/2022 at 08:30 am Sampo plc’s share buybacks 28/06/2022 On 28/06/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,24842.24AQEU24,42242.25CEUX8,67542.27TQEX85,16742.21XHELTOTAL132,51242.22 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 1,841,919 Sampo A shares representing 0.35 per cent of the total number of shares in Sampo plc. Details of ea

IMCD recognised by Sustainalytics as 2022 ESG Industry Top Performer, ranking first among traders and distributors29.6.2022 07:00:00 CEST | Press release

ROTTERDAM, The Netherlands (29 June 2022) – IMCD N.V., (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, was recognised by Sustainalytics as an ESG Industry Top Rated Company. With a score of 13.8 (low risk) IMCD ranks first (lowest risk) among over 180 international peers in trading and distribution. It places the company in the top seven percent of almost 15,000 companies assessed worldwide. Sustainalytics, a Morningstar company, is a globally recognised provider of ESG research, ratings and data that supports investors around the world with the development and implementation of responsible investment strategies. Its ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks. In March 2022, IMCD was also included in the newly launched Dutch ESG AEX index, as one of 25 companies demonstrating best Environmental, Social and Governance (ESG) practices. “We are excited and proud

Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care29.6.2022 07:00:00 CEST | Press release

The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients.With laboratory diagnostics involved in more than two-thirds of healthcare decision making, innovative laboratory solutions that enable an accurate and timely diagnosis are crucial to successful treatment.About 17 million new cases of cancer are diagnosed worldwide each year, and nearly 10 million people die from the disease.1 Basel, 29 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey. “With the BenchMark ULTRA PLUS, we are pleased to offer an advanced tissue staining platform, co-developed with lab professionals,” said Thomas Schinec

SIKA EXPANDS PRODUCTION OF CONCRETE ADMIXTURES IN THE USA29.6.2022 07:00:00 CEST | Press release

SIKA EXPANDS PRODUCTION OF CONCRETE ADMIXTURES IN THE USA Sika is bringing a new manufacturing plant for concrete admixtures on stream in Stafford, Virginia. With the opening of the plant near Washington D.C., Sika is increasing its production capacity in the important American construction market so that it can readily satisfy the strong demand in the Northeast and Mid-Atlantic regions. With over 75 million inhabitants, the urban centers in the Northeast, like New York, Philadelphia, or Boston, are very densely populated and account for more than 25% of US economic output. The new plant is well positioned to support the additional needs of the announced infrastructure program of CHF 200-250 billion in the aforementioned two regions. Sika has been benefiting from the strong demand in the construction sector over recent years. The new facility in Stafford is the second-biggest manufacturing plant for Sika concrete admixtures in the USA. Together with the existing plant in Fairless Hills

TGS ASA and Magseis Fairfield ASA Announce a Recommended Voluntary Exchange Offer by TGS to Acquire All Shares of Magseis29.6.2022 07:00:00 CEST | Press release

OSLO, Norway (29 June 2022) - TGS ASA (“TGS”, OSE: TGS) and Magseis Fairfield ASA (“Magseis”, OSE: MSEIS) announce today that they have entered into a transaction agreement (the "Transaction Agreement") whereby TGS on and subject to certain terms and conditions will put forward a voluntary exchange offer (the “Offer”) to acquire all shares of Magseis for a consideration to the Magseis shareholders in the form of 0.0426 ordinary shares of TGS and NOK 2.30 in cash per Magseis share (the “OfferConsideration”). Based on the closing price of TGS on 28 June 2022, the value of the Offer Consideration is equal to NOK 8.6048 per Magseis share, and the Offer values the total issued share capital of Magseis at approximately NOK 2,333 million. The board of directors of Magseis (the "Board") has unanimously resolved to recommend the Offer. Magseis shareholders, including the largest shareholder, Fairfield MS, LLC, and members of the Magseis Board and management, who collectively own 33.4% of the ou